A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care

Maria Rosa Dalmau Llorca, Alessandra Queiroga Gonçalves, Emma Forcadell Drago, José Fernández-Sáez, Zojaina Hernández Rojas, Josep Maria Pepió Vilaubí, Dolores Rodríguez Cumplido, Rosa Maria Morral Parente, Carina Aguilar Martín, Maria Rosa Dalmau Llorca, Alessandra Queiroga Gonçalves, Emma Forcadell Drago, José Fernández-Sáez, Zojaina Hernández Rojas, Josep Maria Pepió Vilaubí, Dolores Rodríguez Cumplido, Rosa Maria Morral Parente, Carina Aguilar Martín

Abstract

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular AF (NVAF) patients.

Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the Catalan Institute of Health (ICS).

Methods and analysis: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control).

Population: patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the intervention group. The information system for primary care research development database will be used for the data extraction. Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the intervention.

Ethics and dissemination: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d'Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals.

Trial registration: Clinical-Trials.gov: NCT03367325.

Conflict of interest statement

The authors disclose no conflicts of interest.

Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

Figures

Figure 1
Figure 1
Study flowchart. ICS = Catalan Institute of Health.

References

    1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.
    1. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461–8.
    1. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–53.
    1. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410–6.
    1. Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, et al. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Rev Esp Cardiol (Engl Ed) 2013;66:545–52.
    1. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2017;38:2137–49.
    1. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003;22:118–23.
    1. Kirchhof P, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471–4.
    1. Slot KB, Berge E, Dorman P, et al. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008;336:376–9.
    1. Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth atrial fibrillation network/European Heart Rhythm Association consensus conference. Europace 2016;18:37–50.
    1. Spanish Agency of Medicines and Health Products. Therapeutic positioning report UT-ACOD/V5/211120162016. Criteria and general recommendations for the use of direct oral anticoagulants (DOACs) in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. November 2016. Available in: [Accessed November 15, 2017].
    1. Deitelzweig S, Luo X, Gupta K, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017;23:1191–201.
    1. Troncoso Mariño A, Diogène Fadini E. Analysis of the adequacy of the prescriptions with dabigatran. Butlletí E-farma de l’RSB 2012;18. Available in: [Accessed November 15, 2017].
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236–9.
    1. Singer DE, Hellkamp AS, Yuan Z, et al. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2015;4:e001349.
    1. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: management. Clinical Guideline CG180. August 2014. Available in: [Accessed November 17, 2017].
    1. Karlsson LO, Nilsson S, Charitakis E, et al. Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting. Am Heart J 2017;187:45–52.
    1. Beeler PE, Bates DW, Hug BL. Clinical decision support systems. Swiss Med Wkly 2014;144:w14073.
    1. Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision-support systems: a systematic review. Ann Intern Med 2012;157:29–43.
    1. Lobach D, Sanders GD, Bright TJ, et al. Enabling health care decisionmaking through clinical decision support and knowledge management. Evid Rep Technol Assess (Full Rep) 2012;1–784.
    1. Cook DA, Enders F, Caraballo PJ, et al. An automated clinical alert system for newly-diagnosed atrial fibrillation. PloS One 2015;10:e0122153.
    1. Pearson SA, Moxey A, Robertson J, et al. Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990–2007). BMC Health Serv Res 2009;9:154.
    1. Tamblyn R, Ernst P, Winslade N, et al. Evaluating the impact of an integrated computer-based decision support with person-centered analytics for the management of asthma in primary care: a randomized controlled trial. J Am Med Inform Assoc 2015;22:773–83.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi